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a b s t r a c t
Background: Skeletal-related events (SREs; pathologic fracture, radiation or surgery to bone, spinal cord
compression) frequently occur in patients with advanced cancer with bone metastases/lesions. Limited
data on the associated patient and economic burden are available to aid in resource planning and
evaluating treatment options.
Methods: Patients with bone metastases/lesions secondary to breast, lung or prostate cancer or multiple
myeloma; with at least one SRE within 97 days prior to enrollment; life expectancy of at least 6 months;
and Eastern Cooperative Oncology Group performance status 0, 1 or 2 were recruited. Information on
health resource utilization (HRU; including number/duration of hospitalizations, outpatient visits,
procedures), attributed by investigators to be associated with a SRE, was collected retrospectively for
up to 97 days prior to enrollment and prospectively for up to 18–21 months.
Results: A total of 631 patients contributing 1282 SREs, were enrolled across Germany, Italy, Spain and
the United Kingdom. Approximately a third of all SREs required an inpatient stay. Mean duration of
inpatient stay for patients with SREs requiring one ranged from 8.4 to 41.1 days across all countries and
SRE types.
Conclusion: All types of SREs are associated with substantial HRU burden. Preventing SREs by using the
best therapeutic options available may help to reduce the burden to patients and healthcare systems.
& 2014 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bone is a common site for metastasis in advanced cancer;
reports suggest that approximately 65–75% of patients with
advanced breast and prostate cancer, and 30–40% of patients with
advanced lung, kidney or thyroid cancer, will develop bone
metastasis. Almost all patients with multiple myeloma develop
lytic bone disease [1,2]. Owing to the inherent nature of their
manifestation, osteolytic lesions (commonly seen in patients who
have lung or breast cancer or multiple myeloma) can be related to
severe pain, pathologic fractures, life-threatening hypercalcemia,
spinal cord compression and other nerve-compression syndromes
[3]. In contrast, patients with prostate cancer have predominantly
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osteoblastic lesions that can also be frequently associated with
bone pain, as well as pathologic fractures and spinal cord com-
pression owing to the poor quality of bone formed during the
remodeling process [3] and the often osteoporotic state induced
by prolonged castration. These skeletal complications are com-
monly categorized as skeletal-related events (SREs) and deﬁned as
pathologic fracture, radiation to bone, spinal cord compression
and surgery to bone. History of previous SREs is associated with an
increased risk for subsequent events and a poorer prognosis.
Previous studies have demonstrated decreased survival rates in
those patients who have bone metastases and prior SREs [4,5].
Although bone metastases/lesions and their associated SREs are
predictors for increased mortality [4,6–8], patients with advanced
cancer today are generally surviving longer as new and more
effective treatment options are introduced into the therapeutic
armamentarium. Thus, prevention of SREs becomes even more
important as patient life-span is extended.
Apart from their association with severe pain and reduced
quality of life, SREs require substantial healthcare resource utiliza-
tion (HRU) in their treatment and management. Previous retro-
spective studies have attempted to quantify various aspects of the
burden of SREs across speciﬁc tumor types/countries, with studies
in the United States of America (USA), France, Portugal and Spain
all reporting high costs associated with SREs [9–14]. However,
these studies did not address the overall HRU burden. With the
current cost restraints across European healthcare systems inﬂu-
encing resource reimbursement, this information is important
when planning future healthcare requirements and evaluating
new treatment options to prevent skeletal complications. Thus,
our observational, multinational study was designed to estimate
HRU related to each of the deﬁned SRE types in patients with
breast, lung or prostate cancer, or multiple myeloma. Owing to the
high incidence of these malignancies [15] and the frequency of
associated bone metastases [1,2] these cancers can be considered
to be responsible for the majority of the burden associated with
bone metastases and their related complications in clinical prac-
tice. The study was carried out in Canada, Germany, Italy, Spain,
the United Kingdom (UK) and the USA. Herein we report data for a
cohort from 4 European countries.
2. Materials and methods
2.1. Patients
Patients were eligible if they were aged at least 18 years, had
evidence of one or more bone metastasis secondary to breast,
prostate or lung cancer or had multiple myeloma with focal lytic
bone disease, and had experienced at least one SRE in the 97 days
prior to enrollment. Other eligibility criteria included an Eastern
Cooperative Oncology Group (ECOG) performance status of 0, 1 or
2 and life expectancy of at least 6 months; these criteria were used
because patients with shorter life expectancies or worse perfor-
mance statuses are more likely to be treated in hospices or
managed care facilities, where information is often not transferred
to hospital patient charts and thus not accessible to the study
investigators. Patients provided signed, informed consent prior to
collection of their data. Exclusion criteria included participation in
an investigational drug trial for the treatment of bone metastases
or SREs.
2.2. Study design
A multicenter, observational study was conducted in centers
across four major European countries (Germany, Italy, Spain and
the UK) as well as Canada and the USA. Large countries were
chosen to help meet our enrollment targets. Planned enrollment
was 250 patients per country; annual attrition (dropout and
death) was assumed to be 20% for breast cancer and myeloma,
38% for prostate cancer and 55% for lung cancer. Therefore, a
country accruing 250 participants had an expected total follow-up
of 281 patient-years. Analysis of study results per country was pre-
speciﬁed in the protocol; these analyses review HRU by country
and SRE type.
SREs were classiﬁed by the investigators as one of the follow-
ing: pathologic fracture, radiation to bone, spinal cord compres-
sion or surgery to bone. In order to ensure that adequate numbers
of each SRE type per tumor group were recorded for the analysis,
enrollment targets for the index SRE types were established for
each country. Patients were enrolled within 97 days of experien-
cing the index SRE and patients were planned to be followed for
up to 18–21 months. In case of a patient experiencing more than
one SRE in the 97 days prior to enrollment, the index SRE was
selected using the following hierarchy: (1) spinal cord compres-
sion; (2) surgery to bone; (3) pathologic fracture; and (4) radiation
to bone.
The study was planned to run for 30 months after enrollment
of the ﬁrst patient and thus not all patients received the full
duration of follow-up. Baseline demographics and medical history
were collected at enrollment. HRU data were collected retro-
spectively for up to 97 days before study enrollment and pro-
spectively for up to 18–21 months or until the end of the study.
Associated HRU data collected from patient charts included
information relating to inpatient stays, outpatient visits, emer-
gency room visits, nursing home/long-term care facility stays,
home health visits, procedures and certain medications. HRU
was independently attributed to each SRE by the investigators.
Data were requested to be collected from the patient's chart at
least every 90 days during the follow-up observation period to
ensure the identiﬁcation and collection of any prospectively
occurring SREs and resource use.
Enrollment began in 2008 and the data cut-off for this primary
analysis was 31 May 2010.
2.3. Objectives
The primary study objective was to estimate HRU associated
with SREs by type of SRE, tumor type and country. Secondary
objectives, not discussed in this paper, included measurement of
utility-based health-related quality of life following incident SREs,
description of patterns of bisphosphonate use in patients with
bone metastases and description of the association between
bisphosphonate use and changes in renal function.
2.4. Outcome measures
This paper reports the primary outcome measures for HRU,
including inpatient stays, outpatient visits, procedures, emergency
room visits, nursing home/long-term care facility stays and
home health visits. Details of these outcome measures are listed
in Table 1. Secondary outcome measures, not discussed here,
included measures of patient-reported outcomes (the 5-domain
EuroQol questionnaire), bisphosphonate use (type, date of initia-
tion/discontinuation, dose and frequency) and renal data (serum
creatinine level, creatinine clearance rate, glomerular ﬁltration
rate, date of renal impairment/failure, and end-stage renal disease
and dialysis).
2.5. Statistical methods
All analyses in this observational study were descriptive.
Participants who met the eligibility criteria and were enrolled
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into the study were included in the analysis set. Descriptive
analyses of HRU were produced for each SRE type by country.
SREs were planned to be summarized by patient-year. The SRE
rate per patient-year was deﬁned as the ratio of total occurrences
of SREs divided by the patient-years at risk on study. The patient-
years at risk were the sum total duration of follow-up (up to 97
days before enrollment and prospective follow-up after enroll-
ment) among all patients.
The proportion of SREs requiring an inpatient stay was calcu-
lated and summarized. Mean duration of an inpatient stay was
computed as the total of the number of inpatient stay days
attributed to SREs divided by the total number of SREs associated
with an inpatient stay. All other primary outcome measures were
analyzed in the same way.
If radiation to bone or surgery to bone was carried out as a
result of another SRE (i.e. treatment of a primary SRE), the
investigator had the option to attribute HRU to the primary SRE.
In these instances, the inclusion of radiation to bone or surgery to
bone as distinct SREs with no associated HRU in the analysis
would result in an underestimation of the mean HRU for these SRE
types. Thus, in these cases the SREs were excluded from the HRU
analyses.
2.6. Ethics
The protocol and informed consent form were approved by the
Ethics Committee/Institutional Review Boards at each participat-
ing site. Research was carried out in compliance with the Declara-
tion of Helsinki.
3. Results
3.1. Study population
At the time of the primary data analysis (cut-off date, 31 May
2010), a total of 631 patients were enrolled across 95 sites in
Germany, Italy, Spain and the UK, contributing 1282 SREs. By
tumor type, 223 patients had a primary diagnosis of breast cancer
(35.3%), 135 patients had lung cancer (21.4%), 120 patients had
prostate cancer (19%) and 153 patients had multiple myeloma
(24.2%). Baseline demographics and disease characteristics were
similar across the countries (Table 2), although the proportions of
female patients enrolled in Spain (44%) and the UK (42%) were
lower than those in Germany (58%) and Italy (60%). Patients
enrolled in Spain and the UK generally had a poorer performance
status than those enrolled in Germany and Italy, although numeri-
cally fewer patients in the UK (versus the other three countries)
had experienced an SRE prior to enrollment into the study. With
the exception of the UK, over half of patients included in the study
had experienced a prior SRE at baseline, despite the relatively
short median time since diagnosis of bone metastases.
3.2. Disposition
The median length of prospective follow-up across all countries
and tumor types was in the range of 4.6–8.1 months. For patients
with breast cancer, median follow-up across the four countries
ranged from 6.9 to 10.9 months; for patients with lung cancer,
median follow-up was shorter (from 1.5 to 5.6 months); for
patients with prostate cancer it was 4.6–9.4 months; and for
patients with multiple myeloma it was 5.5–10.8 months.
Across all tumor types, 48% (n¼96) of German patients
discontinued the study prior to the primary data analysis cut-off
date; death was the primary reason for early discontinuation
(n¼82). In Italy, 39% (n¼66) of patients discontinued the study
early, with death again the primary reason for early discontinua-
tion (n¼59). Similarly in Spain and the UK, 38% (n¼50) and 45%
(n¼59) discontinued the study early, with death cited as the
primary reason in 39 and 58 patients, respectively.
3.3. Skeletal-related events
Patients experienced a total of 1282 SREs (Table 3), including
108 SREs that were recorded and subsequently discounted from
Table 1
Study health resource utilization outcome measures.
Outcome measure Data collected
Inpatient stays Number, duration, reason, type of hospital unit, time spent in each type of hospital unit
Outpatient visits Number, reason, provider type (e.g. medical oncologist, radiation oncologist,
urologist, primary care physician, physiotherapist, occupational therapist)
Procedures Type of procedure (e.g. imaging or treatment), reason for procedure, facility type
Emergency room visits Number of visits, reason for visits, disposition (e.g. admitted to hospital, discharged)
Nursing home/long-term care facility stays Type of facility (e.g. hospice, rehabilitation), reason for admission, length of stay
Home health visits Number of visits, provider type, reason for visits
Certain medications Including systemic therapies (e.g. chemotherapy)
Table 2
Baseline demographics and disease characteristics of the study population.
Germany
(N¼200)
Italy
(N¼168)
Spain
(N¼131)
UK
(N¼132)
Age, years,
mean (SD)
64 (10) 63 (11) 63 (11) 66 (12)
Female, n (%) 115 (58) 100 (60) 58 (44) 55 (42)
Race, n (%)
White/Caucasian 198 (99) 167 (99) 128 (98) 127 (96)
Other 2 (1) 1 (1) 3 (2) 5 (4)
Tumor type, n (%)
Breast 85 (43) 62 (37) 31 (24) 45 (34)
Lung 34 (17) 43 (26) 41 (31) 17 (13)
Prostate 30 (15) 24 (14) 21 (16) 45 (34)
Multiple myeloma 51 (26) 39 (23) 38 (29) 25 (19)
ECOG performance status, n (%)
0 55 (28) 43 (26) 24 (18) 27 (20)
1 102 (51) 79 (47) 53 (40) 56 (42)
2 43 (22) 46 (27) 54 (41) 49 (37)
History of SREs,a n
(%)
124 (62) 95 (57) 92 (70) 51 (39)
Time since primary cancer diagnosis, months
Mean (SD) 55 (68) 41 (56) 46 (61) 52 (56)
Median 29 13 17 33
Time since bone metastases, months
Mean (SD) 16 (25) 16 (29) 16 (29) 19 (28)
Median 3 4 3 8
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; and SRE,
skeletal-related event.
a Before the retrospective data collection period.
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the HRU analysis (70 events of radiation to bone and 38 events of
surgery to bone) because their management was associated with
the treatment of a separate primary SRE. The majority of the
events recorded (62–78% range across countries) were retrospec-
tive, i.e. occurred before study enrollment. Radiation to bone was
the most commonly reported SRE reported across all countries
(Germany, 269 of 432 events; Italy, 164 of 291 events; Spain, 133 of
243 events; UK, 196 of 316 events).
Patient-year-adjusted SRE rates for each SRE type were gen-
erally consistent across countries: 2.2 SREs per patient-year in
Germany, 1.9 SREs per patient-year in Italy, 2.4 SREs per patient-
year in Spain and 2.9 SREs per patient-year in the UK.
3.4. HRU analyses
Across all countries, approximately one in three SREs required
an inpatient stay (mean hospitalizations per SRE ranged from 0.31
to 0.36 across all countries) (Fig. 1A). Spinal cord compression and
surgery to bone were consistently associated with a higher
requirement for inpatient stays than pathologic fracture and
radiation to bone (Table 4; Fig. 1A). Radiation to bone was
associated with the lowest mean number of inpatient stays,
ranging from 0.1 to 0.2 hospitalizations per event across all
countries.
In Germany and the UK, mean length of inpatient stays was
similar, at 19.1 days and 18.3 days, respectively (among SREs that
required an inpatient stay) (Fig. 1B). For Italy and Spain, this ﬁgure
was slightly higher at 21.6 and 22.5 days, respectively. Spinal cord
compressions were associated with the longest inpatient stays,
ranging from 25.6 days to 41.1 days across the four countries
(Table 4; Fig. 1B). Although radiation to bone was less frequently
associated with the requirement for an inpatient stay, those events
requiring an inpatient stay were associated with stays of consider-
able duration (mean, 10.4–21.9 days across the four countries).
Mean duration of an inpatient stay varied numerically by facility
type, although the sample sizes were small and made interpreta-
tion difﬁcult. In Germany, mean duration of inpatient stays across
those SREs requiring an inpatient stay ranged from 3.0 days in an
urology unit/ward (n¼1) to 33.0 days in a gynecology unit/ward
(n¼1). For Italy, the duration of inpatient stays per SRE was
equally widespread across facility types, ranging from 2.0 days in
an intensive care unit/ward to 44.0 days in a rehabilitation facility.
In Spain, the differences between the duration of stay by facility
type were smaller, with a range of 7.0 days in an ‘unknown’ unit
(n¼1) to 30.6 days in a unit marked as ‘other’ and not further
deﬁned (n¼14). Mean duration of stay per SRE by facility type in
the UK ranged from 2.0 days in an ‘unknown’ unit (n¼1) to a
notable 58.5 days spent in a nursing facility.
Approximately two-thirds of SREs required at least one out-
patient visit (68%, 74%, 66% and 78% of SREs in Germany, Italy,
Spain and the UK, respectively). SREs were associated with a mean
number of 6.7, 4.5, 4.8 and 2.6 outpatient visits per SRE in each of
the countries, respectively (Fig. 2A). Aside from those patients
treated in the UK, radiation to bone (versus the other SRE types)
was associated with the highest number of outpatient visits
(Table 4; Fig. 2A). The SRE type requiring the most outpatient
visits in the UK was spinal cord compression; in all other
countries, this was the second highest event type requiring out-
patient visits.
The majority (490%) SREs required at least one procedure to
be performed. The mean number of procedures associated with
each SRE was 9.9, 6.4, 7.2 and 3.4 for Germany, Italy, Spain and the
UK, respectively (Fig. 2B). Reﬂecting the pattern of outpatient
visits, for Germany, Italy and Spain, radiation to bone was
associated with the highest mean number of procedures, with
13.2, 8.0 and 9.0 procedures per event, respectively (Table 4). The
number of procedures per radiation to bone event was much
lower than this in the UK (2.2 procedures per SRE), which was
reﬂected in the lower rates of external beam radiation and
intensity modulation radiotherapy procedure used in this country
than in Germany, Italy and Spain (Table 5). Types of procedures
used per SRE also differed by SRE type: for example, magnetic
resonance imaging was frequently used for spinal cord compres-
sion, ranging from 0.7 to 1.1 procedures per SRE across the four
countries, whereas it was used much less often for the other SREs
(Table 5). In Germany, outpatient or emergency room visits were
associated with a mean of 7.6 procedures per SRE, while inpatient
stays were associated with a mean of 2.3 procedures per SRE. The
mean number of procedures associated with outpatient/emer-
gency room visits (4.7 and 5.0 procedures per SRE) versus those
carried out during in-patient stays (1.8 and 2.2 procedures per
SRE) for Italy and Spain, respectively, was similar. The number of
procedures employed per SRE was consistently lower in the UK,
where outpatient/emergency room visits were associated with a
mean number of 2.6 procedures per SRE versus only 0.9 procedures
per SRE in the inpatient setting.
Emergency room visits were generally infrequently reported
(Table 4). Few nursing home/long-term care facility stays and
home health visits were reported for all countries (Table 4).
4. Discussion
This is the ﬁrst large, multinational study including both
prospectively and retrospectively collected data to examine the
HRU associated with the different categories of SREs – local,
irreversible consequences of bone metastases – in a large sample
of patients from four major European countries. Previous studies
have either been solely retrospective in nature or have limited
their research to a single tumor type. Furthermore, this study
captured SRE-speciﬁc data that have not previously been exten-
sively estimated, including outpatient and emergency room visits
as well as detailed information on types of procedure. In addition,
HRU was directly attributed to SREs by the investigators, thus HRU
was only assigned when it was deemed to be directly due to the
SRE and not to the underlying disease.
Although the distribution of SREs reported in this study is not
representative of the real-world distribution of SREs (enrollment
Table 3
Summary of skeletal-related events (SREs) by country and SRE type (pooled tumor types).
Germany (N¼432) Italy (N¼291) Spain (N¼243) UK (N¼316)
PF RB SCC SB PF RB SCC SB PF RB SCC SB PF RB SCC SB
Number of SREs, n (%) 85
(20.0)
269
(62.0)
13
(3.0)
65
(15.0)
66
(22.7)
164
(56.4)
12
(4.1)
49
(16.8)
51
(21.0)
133
(54.7)
32
(13.2)
27
(11.1)
52
(16.5)
196
(62.0)
34
(10.8)
34
(10.8)
Patient-year-adjusted
SRE rate
0.4 1.4 0.1 0.3 0.4 1.1 0.1 0.3 0.5 1.3 0.3 0.3 0.5 1.8 0.3 0.3
PF, pathologic fracture; RB, radiation to bone; SB, surgery to bone; SCC, spinal cord compression; and SRE, skeletal-related event.
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was driven by the index SRE recruitment cells), it can be concluded
that all SRE types were associated with substantial HRU, and the
pattern of HRU was generally consistent within each SRE type
across all countries. Notably, approximately a third of all SREs were
associated with an inpatient stay. Surgery to bone and spinal cord
compression were the SRE types most likely to result in hospita-
lization. The mean duration of inpatient stays was considerable
across all SRE types, ranging from 18 days in the UK to 19 days in
Germany and 22 days in Italy and Spain. Although radiation to
bone was the SRE type the least likely to require an inpatient stay,
those events requiring hospitalization were associated with stays
of notable duration (up to 23 days in length). The duration of
inpatient stay varied by country and facility type. For example,
mean length of stay for surgery to bone was lower in Spain and the
UK (8.4 and 10.0 days, respectively) than in Germany and Italy
(19.4 and 19.8 days, respectively). This could reﬂect differences in
clinical practice and available resources between countries, such as
the frequency of use of less invasive surgical procedures and
whether subsequent physiotherapy and rehabilitation is per-
formed in a continued inpatient setting or in an outpatient setting.
However, caution is needed when interpreting these data because
the numbers of SREs are low when split by both SRE type and
country. Across all countries, radiation units/wards were asso-
ciated with substantial inpatient stays (mean 15.50, 12.00, 18.40
and 8.67 days, respectively, for Germany, Italy, Spain and the UK),
suggesting that patients may be required to travel and remain in
hospital while receiving treatment.
All SREs were associated with multiple outpatient visits and
numerous procedures. Events of radiation to bone were associated
with a lower rate of outpatient visits and procedures in the UK
(versus Germany, Italy and Spain), which likely reﬂects differences
in clinical practice between the UK and the other three European
countries. In the UK, there is a preference to use single-fraction
radiotherapy versus the multi-fractionated approach that is favored
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Fig. 1. (A) MeanþSD number of inpatient stays per SRE and (B) meanþSD length of hospital stays per SRE (excluding SREs without a stay), by country and SRE type.
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Table 4
HRU by country and skeletal-related event type (pooled tumor types).
Germany Italy Spain UK
PF RB SCC SB PF RB SCC SB PF RB SCC SB PF RB SCC SB
Inpatient hospitalizations, n
Mean (SD) 0.4 (0.7) 0.2 (0.4) 0.9 (0.9) 0.9 (0.6) 0.5 (0.7) 0.2 (0.5) 0.7 (0.8) 0.8 (0.6) 0.5 (0.6) 0.2 (0.4) 0.5 (0.6) 0.8 (0.4) 0.4 (0.6) 0.1 (0.2) 1.1 (0.8) 0.8 (0.5)
Median 0 0 1.0 1.0 0 0 0.7 1.0 0 0 0.5 1.0 0 0 1.0 1.0
Length of stay, daysa
Mean (SD) 18.7 (11.6) 18.0 (12.5) 25.6 (23.0) 19.4 (19.7) 22.4 (15.0) 16.6 (11.0) 41.1 (29.8) 19.8 (24.2) 20.2 (20.2) 21.9 (15.0) 34.3 (37.9) 8.4 (6.0) 20.7 (17.1) 10.4 (10.7) 27.7 (22.3) 10.0 (7.8)
Median 21.5 16.0 14.0 15.0 21.5 15.0 32.0 10.0 13.0 19.0 28.0 8.0 14.5 6.5 23.0 7.5
Outpatient visits, n
Mean (SD) 3.1 (6.3) 9.3 (7.6) 5.4 (7.4) 1.6 (5.1) 2.9 (4.4) 6.0 (5.1) 4.1 (6.8) 1.4 (2.5) 1.9 (2.7) 6.9 (6.7) 3.3 (5.4) 1.9 (3.3) 2.2 (2.6) 2.7 (2.9) 3.4 (4.4) 2.2 (2.5)
Median 0.5 8.0 1.0 0 1.0 5.0 1.0 0.5 1.0 7.0 0 0.5 1.0 1.5 1.5 2.0
Procedures, nb
Mean (SD) 5.2 (7.3) 13.2 (7.1) 8.9 (8.7) 3.0 (4.4) 4.6 (5.4) 8.0 (5.0) 7.8 (6.3) 2.9 (2.8) 3.6 (3.4) 9.0 (5.8) 7.8 (5.3) 3.8 (3.3) 3.1 (2.9) 3.0 (2.7) 6.2 (4.7) 3.7 (4.0)
Median 2.0 12.5 2.0 2.0 3.0 7.5 6.0 2.0 2.5 10.0 7.0 2.5 2.0 2.0 5.0 3.0
Emergency room visits, n
Mean (SD) 0 (0.1) 0 (0) 0 (0) 0 (0) 0.1 (0.4) 0 (0) 0.2 (0.4) 0 (0.2) 0.1 (0.3) 0 (0.2) 0.2 (0.5) 0 (0) 0.2 (0.5) 0 (0) 0.2 (0.6) 0 (0)
Median 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Nursing home/long-term care facility stays, n
Mean (SD) 0 (0) 0 (0) 0 (0) 0 (0.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0.2) 0 (0) 0 (0.2) 0 (0) 0 (0.2) 0 (0)
Median 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Home health visits, n
Mean (SD) 0 (0) 0 (0.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0.2) 0 (0) 0 (0) 0 (0.1) 0.1 (0.2) 0 (0.2)
Median 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
HRU, health resource utilization; PF, pathologic fracture; RB, radiation to bone; SB, surgery to bone; SCC, spinal cord compression; SD, standard deviation; and SRE, skeletal-related event.
a Based on SREs requiring an inpatient stay.
b Including imaging.
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in the majority of European countries. This preference for single-
fraction treatment was also reﬂected in the lower proportion of
radiation to bone events requiring an inpatient stay in the UK and
the shorter duration of associated stay, compared with the other
three countries.
One of the limitations with the study was that the duration of
follow-up was shorter than planned (up to a median of 8.1 months
in this European cohort). Slow recruitment (study period was
deﬁned as 30 months following enrollment of the ﬁrst patient)
and early withdrawal from the study due to patient death may
have been the main contributing factors. Withdrawal from the
study was slightly higher than predicted, with death the primary
reason for early discontinuation despite the inclusion criteria
stating patients should have a life expectancy of at least 6 months.
This could reﬂect the challenges associated with physicians'
estimation of patients' life expectancies [16]. Slow recruitment
also contributed to small sample size per SRE in some countries,
which limits interpretation of some of the results. This may in part
be due to difﬁculties with engaging patients and their physicians
in observational research when no active therapies/interventions
are offered as part of the study and participation in a concurrent
investigational study is not permitted. However, the data show a
generally consistent approach to patient management across
countries, which suggests that the outcomes are valid, even
though small sample numbers may prevent detailed interpreta-
tion. Another potential limitation was that we did not use an
independent, blinded review for attributing HRU to SREs; how-
ever, there were no external inﬂuences on the local investigators,
therefore their attribution of HRU should be reﬂective of clinical
practice on a local level.
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Fig. 2. (A) MeanþSD number of outpatient visits per SRE and (B) meanþSD number of procedures performed per SRE, by country and SRE type. (B) Includes both outpatient
and procedures (i.e. imaging, surgery, etc.). Radiation procedures with multiple sessions were captured as multiple procedures. PF, pathologic fracture; RB, radiation to bone;
SB, surgery to bone; SCC, spinal cord compression; SD, standard deviation; and SRE, skeletal-related event.
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Despite the robust approach of this study, the HRU observed
may underestimate the overall resource burden associated with
SREs for patients with bone metastases due to advanced cancer.
Patients with low performance status and limited life expectancy
(ECOG performance status 3 or 4 or a life expectancy of o6
months) were excluded from this study, although they may
arguably utilize substantial healthcare resources during the late
stage of their disease. Some data were not accessible to the
investigators at all study sites, i.e. information relating to home
health visits and/or long-term care facility stays were often not
recorded in the hospital patient charts. Emergency room visits
were often not reported or required; in case of an emergency, a
patient may have contacted the treating specialist department
directly for admission or treatment. Furthermore, in case of an
emergency, patients may have attended an emergency room in a
different center to that of the participating institute and this
information may therefore not be transferred to the patient chart.
In addition, indirect costs (i.e. transport to and from treatment
units and the costs to employers as a result of patients and their
care givers taking time off work) that are incurred as a result of
SREs were not available to the investigators and not included in
the study, Finally, bone pain requiring analgesic use or changes in
anticancer therapy to manage tumor burden in the bone are
frequent in patients with advanced cancer and bone metastases.
These events were not deﬁned as SREs, although they may require
additional inpatient stays and/or outpatient visits.
HRU resulting from SREs is of increasing relevance in times of
ﬁnancial and economic restraint because it can help to determine
the ﬁnancial burden to hospital managers and payers. A separate
analysis of the costs associated with SREs in this study found that
the most costly SRE, spinal cord compression, had a mean cost per
SRE of €4884–€12,082, and costs per surgery to bone ranged from
€3348 to €9407. Pathologic fracture and radiation to bone had
slightly lower costs per SRE (€1015–€6968 and €704–€2461,
respectively) but still represented a considerable ﬁnancial burden
[17]. Treatments that delay or prevent SREs could help to reduce
the utilization of healthcare resources, thereby lowering the costs
associated with metastatic bone disease. Historically, intrave-
nously administered bisphosphonates, such as zoledronic acid,
have been the mainstay of treatment for the prevention of SREs in
adult patients with advanced malignancies involving the bone
[18]. More recently, the RANK ligand inhibitor denosumab has
been widely approved for the prevention of SREs in adults with
bone metastases from solid tumors [19] after it was demonstrated
to be superior to zoledronic acid in an integrated analysis of
patients with solid tumors from three identically designed, phase
3, head-to-head clinical trials [20]. The systemic treatments
enzalutamide, abiraterone acetate and radium-223 dichloride,
currently only available for use in patients with metastatic
castration-resistant prostate cancer, have shown a trend towards
delayed bone complications compared with placebo in phase
3 trials [21–23]. In these studies, concomitant use of bone-
targeted agents was permitted and preliminary data demonstrated
a further trend towards improved outcomes in patients who
received additional bone-targeted therapy. As bone outcomes
were not a primary focus for these studies, the extent to which
these new agents protect against SREs should be further assessed
[23–25].
5. Conclusion
Data from Germany, Italy, Spain and the UK suggest that all
types of SRE occurring in patients with bone metastases/lesions
secondary to breast, prostate or lung cancer or multiple myeloma
are associated with substantial HRU (lengthy inpatient stays,
numerous outpatient visits and multiple procedures). Further
studies in additional Western European countries will conﬁrm
whether these observations reﬂect the situation across Western
Europe. Preventing SREs by using the optimal treatment option
available is important to achieve a considerable reduction in
patient burden and rate of hospitalization.
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Table 5
Number of proceduresa performed by country, per SRE by SRE type (pooled tumor
types).
Procedure type Mean (SD)
Germany Italy Spain UK
Pathologic fracture N ¼ 85 N ¼ 66 N ¼ 51 N ¼ 52
Chemotherapy 0 (0.1) 0.2 (0.9) 0 (0) 0.2 (1.1)
Computed tomography 0.4 (0.6) 0.4 (0.6) 0.2 (0.5) 0.3 (0.5)
External beam radiation 2.9 (6.3) 1.3 (4.8) 0.7 (2.3) 0.7 (1.8)
Intensity modulation radiotherapy 0.2 (1.3) 0 (0) 0.1 (0.3) 0 (0)
Laboratory assessment 0.1 (0.2) 0.4 (1.2) 0 (0.1) 0.1 (0.3)
Magnetic resonance imaging 0.2 (0.5) 0.2 (0.5) 0.5 (0.6) 0.2 (0.5)
Physical examination 0.1 (0.3) 0.4 (0.7) 0.3 (0.7) 0.2 (0.5)
Surgery to bone – extremities 0.1 (0.2) 0.2 (0.4) 0.2 (0.4) 0.2 (0.4)
X-ray 0.5 (0.6) 0.9 (0.9) 1.2 (1.5) 0.8 (1.3)
Other 0.6 (1.8) 0.3 (0.9) 0.2 (0.6) 0.4 (0.9)
Radiation to bone N ¼ 250 N ¼ 154 N ¼ 111 N ¼ 177
Computed tomography 0.2 (0.4) 0.1 (0.4) 0.1 (0.3) 0.1 (0.3)
External beam radiation 7.2 (7.8) 6.8 (5.0) 6.0 (6.2) 2.2 (2.4)
Intensity modulation radiotherapy 4.9 (7.7) 0.3 (1.3) 2.0 (4.1) 0 (0)
Laboratory assessment 0.1 (0.7) 0.2 (0.7) 0.1 (0.5) 0 (0.2)
Physical examination 0.1 (0.3) 0.2 (0.5) 0.4 (0.8) 0.1 (0.4)
Radionucleotides 0.2 (1.8) 0.1 (0.7) 0 (0.1) 0 (0.1)
X-ray 0.1 (0.3) 0.1 (0.3) 0.1 (0.5) 0.2 (0.5)
Other 0.2 (0.6) 0.1 (0.5) 0.2 (0.5) 0.2 (0.5)
Spinal cord compression N ¼ 13 N ¼ 12 N ¼ 32 N ¼ 34
Chemotherapy 0 (0) 0.2 (0.6) 0 (0) 0.2 (0.8)
Computed tomography 0.4 (0.5) 0.6 (0.5) 0.3 (0.6) 0.3 (0.8)
External beam radiation 6.0 (8.1) 4.0 (4.6) 3.8 (4.2) 3.0 (3.4)
Intensity modulation radiotherapy 0.9 (3.3) 0 (0) 1.2 (3.1) 0 (0)
Laboratory assessment 0 (0) 0.8 (1.8) 0.1 (0.3) 0.4 (1.2)
Magnetic resonance imaging 0.7 (0.6) 1.1 (1.7) 1.1 (0.8) 0.9 (0.7)
Physical examination 0.1 (0.3) 0.3 (0.5) 0.1 (0.3) 0.2 (0.6)
Radionucleotides 0 (0) 0 (0) 0 (0) 0.2 (1.0)
Surgery to bone – spine 0.4 (0.5) 0.2 (0.4) 0.1 (0.3) 0.1 (0.4)
X-ray 0.1 (0.3) 0.4 (0.7) 0.6 (1.0) 0.4 (0.9)
Other 0.2 (0.8) 0 (0) 0.3 (1.0) 0.2 (0.5)
Surgery to bone N ¼ 59 N ¼ 36 N ¼ 12 N ¼ 30
Computed tomography 0.2 (0.6) 0.3 (0.6) 0 (0) 0.1 (0.3)
External beam radiation 0.3 (2.0) 0.4 (1.8) 0 (0) 0.4 (2.0)
Laboratory assessment 0.1 (0.4) 0.2 (0.8) 0 (0) 0.4 (1.0)
Magnetic resonance imaging 0.1 (0.3) 0.2 (0.5) 0.1 (0.3) 0.1 (0.4)
Physical examination 0.1 (0.4) 0.2 (0.6) 0.8 (1.7) 0.2 (0.4)
Surgery – other 0.1 (0.3) 0.1 (0.2) 0.5 (0.7) 0 (0)
Surgery to bone – extremities 0.5 (0.5) 0.3 (0.5) 0.3 (0.5) 0.5 (0.5)
Surgery to bone – spine 0.3 (0.5) 0.4 (0.5) 0.3 (0.5) 0.2 (0.4)
Transfusions 0.1 (0.5) 0 (0.2) 0 (0) 0.2 (0.7)
Wound care/debridement 0.3 (1.1) 0 (0) 0.1 (0.3) 0.1 (0.4)
X-ray 0.4 (0.6) 0.6 (0.7) 1.3 (1.6) 1.0 (1.1)
Other 0.5 (2.6) 0.1 (0.4) 0.4 (0.9) 0.3 (0.8)
SRE, skeletal-related event.
a Procedures performed with a mean of at least 0.2 per SRE in at least one of
the countries listed.
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